Pharmafile Logo

The impact of AI and digital health on chronic diseases

Over the past decades, advances in information technology have fundamentally transformed the management of chronic diseases, but what impact is this having on the pharma industry?
- PMLiVE

The economic burden of chronic conditions is immense, encompassing healthcare expenditures, productivity losses and the societal costs of premature mortality. Between 2011 and 2030, the cumulative economic losses attributable to cancer, cardiovascular disease, chronic respiratory diseases, diabetes and mental health disorders are estimated at $47trn. In addition, the global burden of lost life is projected to increase from $22.8trn in 2010 to $43.3trn by 2030.

In contrast, global healthcare spending exceeds $9trn annually, with an estimated $4-7trn directly attributable to chronic conditions. Once a chronic condition develops, it creates significant challenges for patients, healthcare providers, healthcare systems and society at large.

Read the article in full here.

Aleksandar Ruzicic is Founder, Chairman and CEO of Almasan, a specialist healthcare consultancy
14th October 2026
From: Marketing
Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links